miR Scientific is a precision healthcare company committed to improving public health by transforming cancer management globally. The company’s proprietary miR Disease Management Platform® was developed to revolutionize the standard of value-based care for cancers and initially focuses on urological cancers
The initial test delivered by the miR Disease Management Platform® is the miR Sentinel™ Prostate Cancer Test, the first and only standalone, non-invasive liquid biopsy urine test that accurately detects, classifies and can monitor prostate cancer at the molecular level.
The miR Sentinel™ Prostate Cancer Test can transform cancer management by delivering accurate and actionable results to physicians and patients from a single urine sample, answering the two most important questions:
Is cancer present? How severe is it?
This result indicates that the patient finding shows No Molecular Evidence of Prostate Cancer
This result indicates that the patient presents Molecular Evidence of Moderate-Risk Prostate Cancer, which is consistent with the NCCN Favorable Intermediate Risk Group
This result indicates that the patient presents Molecular Evidence of Low-Risk Prostate Cancer, which is consistent with the NCCN Very Low and Low Risk Groups
This result indicates that the patient presents Molecular Evidence of Elevated-Risk Prostate Cancer, which is consistent with the NCCN Unfavorable Intermediate, High, and Very High Risk Groups
Accurately detect and risk-classify Prostate Cancer, giving patients and providers confidence in the information used to plan management or treatment
The miR Sentinel™ Prostate Cancer Test requires a single, contact-free urine specimen, with no related risk of side effects
The prostate naturally releases molecules into urine, including several different kinds of RNA genetic material that vary depending on the absence or presence and severity of prostate cancer. This information obtained from the urine sample is all miR Scientific needs to accurately detect and classify cancer using the miR Sentinel Prostate Cancer Test – it is not reliant on clinical risk factors such as PSA, DRE or biopsy material
The miR Sentinel™ Prostate Cancer Test has been validated for the detection and classification of prostate cancer.
miR Sentinel Prostate Cancer Test can replace an array of multiple blood tests, invasive biopsies and imaging procedures with one comprehensive solution.
Unlike biopsies, MRIs and other current options, the miR Disease Management Platform® is high-throughput and can be easily administered for large volumes of patients.
Prostate cancer is prevalent and deadly.
It represents the highest number of new cancer cases diagnosed annually and is the second leading cause of cancer deaths among men. Early detection and the ability to identify high grade disease early are key to effective disease management.
The current standard of care relies on PSA (Prostate Specific Antigen) and Digital Rectal Exams (DRE) to trigger core needle biopsies for the detection and diagnosis of prostate cancer.
Today’s standard of care is inaccurate, invasive and often results in over-treatment. Up to 70% of diagnostic core needle biopsies are unnecessary and consequently incur cost and morbidities.
The inefficiency and ineffectiveness of today’s standard of care may be a factor in many men completely avoiding the screening process. It is estimated that over 60% of age-eligible men remain unscreened.
Our non-invasive, pain-free miR Sentinel™ Prostate Cancer Test can help healthcare providers, patients, and employers realize true cost-effectiveness and efficiency in prostate cancer detection and management.
Help identify patients with the greatest need by adding miR Sentinel™ Prostate Cancer Test to your detection and classification toolbox.
Experience a non-invasive, accurate, easily-accessible prostate cancer test that delivers helpful results to your provider with a single urine specimen.
Keep your employees and their families healthy and reduce excessive urologic cancer screening, treatment costs and unproductive workdays with a straightforward, validated and highly accessible urine test.
Our molecular diagnostic capabilities are a novel approach to cancer detection and classification, using advanced sncRNA interrogation techniques and a proprietary scoring algorithm.
miR’s technology isolates pre-classified, informative RNA entities from urinary exosomes, and uses proprietary tools to detect and process signals from numerous RNA entities that are evident in the specimens.
The miR Sentinel™ Prostate Cancer Test is healthcare’s first and only standalone urine test that detects and classifies prostate cancers with a high level of accuracy—no rectal exam, blood test, biopsy or strict urine requirements.
miR’s test provides the most comprehensive non-invasive prostate cancer test.